SkinBioTherapeutics receives clearance to launch beauty-from-within food supplement ingredient in France

18 Sep 2023 --- UK-based life science business SkinBioTherapeutics has secured approval from the French health authorities and plans to begin advertising its food supplement AxisBiotix-Ps in France this October.

The product is designed to alleviate symptoms related to the common skin condition Psoriasis, which affects 2 to 3% of the global population and an estimated 2 million French residents. Launching the product in France will generate an additional geographical revenue stream for the company. The exact date has yet to be announced.

The company also received a seal of approval from three other European health authorities earlier this year.

“In line with our strategic plan, we are delighted that AxisBiotix-Ps is now approved for sale in another market, after the previous launches in the UK, Spain, and Italy,” states Stuart Ashman, CEO of SkinBioTherapeutic.

The company further notes that, in the UK, where the supplement was first launched, customer retention rates of over 80% have been sustained.

An innovative solution
Currently, there is no known cure for the lifelong condition Psoriasis. SkinBioTherapeutics asserts that AxisBiotix-Ps offers a long-term approach to managing the symptoms associated with it.

The company further explains that this contrasts with alternative treatments such as steroids and immuno-suppressants, which cannot be used over a long period.

Scientific data suggest this is the case because, as a food supplement, AxisBiotix-Ps offers an innovative solution that acts on the gut-skin axis by reintroducing missing bacteria into the gut and redressing the balance to improve skin health.

Ashman told Nutrition Insight in June, “dermatologists don’t yet know exactly how psoriasis is caused, but several studies have indicated a compromised gut barrier could be a potential cause, although further research is needed.”SkinBioTherapeutics says its offering can help manage long-term psoriasis symptoms.

Continued interest in the EU markets
SkinBioTherapeutics’ presence in a rapidly expanding number of EU markets reflects the company’s ongoing commercialization strategy.

“We anticipate an open reception from potential new customers in our European markets due to their positive attitude to food supplements,” Ashman further states.

Like their counterparts elsewhere in Western Europe, French consumers report high food supplement usage.

A recent survey by Synadiet reveals that one-third of French respondents reported regularly taking advantage of such supplements. This data suggests a promising start for SkinBioTherapeutic in the country’s market.

Following the latest approval by the French health authorities, the company is seeking authorization from another undisclosed EU regulatory agency.

“We have now completed the goal of launching in three major European markets in 2023 and we look forward to updating the market on other country launches next year,” says Ashman.

Edited by Milana Nikolova

To contact our editorial team please email us at editorial@cnsmedia.com